Risk Factors of Immune-Mediated Hepatotoxicity Induced by Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis
Open Access
- 13 November 2024
- journal article
- review article
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 7129-7143
Abstract
Immune checkpoint inhibitors (ICIs) significantly improve survival, while immune-mediated hepatotoxicity (IMH) has been reported. To evaluate the incidence and potential risk factors of IMH among cancer patients treated by ICIs, PubMed/Medline, Web of Science, Cochrane, and Embase were searched before 30 March 2024 for systematic review and meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CI) were calculated. Quality assessment was completed using the Newcastle–Ottawa scale. Of 1217 articles identified, 24 consisting of 9076 patients were included, with one study being prospective and the rest retrospective. The overall incidence of any grade IMH and grade ≥ 3 secondary to ICIs was 14% and 7%, respectively. The cholestatic pattern was more prevalent than the hepatocellular and mixed patterns. The meta-analysis revealed that ICI treatment was related to reduced risk of IMH in older patients (SMD: −0.18; 95% CI: −0.33 to −0.04), individuals with higher body mass index (WMD: −2.15; 95% CI: −3.92 to −0.38), males (OR: 0.44; 95% CI: 0.27 to 0.72), and patients with lung cancer (OR: 0.58, 95%CI 0.41 to 0.83). On the other hand, patients with liver metastasis (OR: 1.80; 95% CI: 1.47 to 2.20), history of ICI treatment (OR: 3.09; 95% CI: 1.21 to 7.89), diabetes (OR: 2.19; 95% CI: 1.36 to 3.51), chronic HBV (OR: 3.06; 95% CI: 1.11 to 8.46), and concomitant use of ICIs (OR: 8.73; 95% CI: 2.41 to 31.59) increased the risk of developing IMH. This study will provide clinicians with information on potentially high-risk groups for IMH, who need to be cautiously monitored for liver function when receiving immunotherapy.Keywords
Funding Information
- Clinical Key subject Construction of Shanghai (shslczdzk06504)
This publication has 54 references indexed in Scilit:
- A multicenter retrospective analysis: Factors influencing hepatic adverse events induced by immunotherapy in advanced liver cancerCancer Reports, 2023
- Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survivalJournal of Cancer Research and Clinical Oncology, 2022
- Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patientsJournal of Cancer Research and Clinical Oncology, 2021
- Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virusCancer Immunology, Immunotherapy, 2021
- Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patientsHepatology International, 2021
- Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancersJournal of Cancer Research and Clinical Oncology, 2020
- Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignanciesJournal of Gastroenterology, 2020
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- Leberschaden durch Therapie mit Immun-Checkpoint-InhibitorenDer Pathologe, 2018
- Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort studyJournal of Gastroenterology, 2014